ZFIN ID: ZDB-PUB-191002-1
Streamlining drug discovery assays for cardiovascular disease using zebrafish
Pott, A., Rottbauer, W., Just, S.
Date: 2019
Source: Expert opinion on drug discovery   15(1): 27-37 (Other)
Registered Authors: Just, Steffen, Pott, Alexander, Rottbauer, Wolfgang
Keywords: Zebrafish, cardiovascular disease, drug discovery, small compound screen
MeSH Terms:
  • Animals
  • Cardiovascular Agents/pharmacology*
  • Cardiovascular Diseases/drug therapy*
  • Disease Models, Animal*
  • Drug Discovery/methods*
  • Drug Evaluation, Preclinical/methods
  • High-Throughput Screening Assays/methods*
  • Zebrafish*
PubMed: 31570020 Full text @ Expert Opin. Drug Discov.
Introduction: In the last decade, our armamentarium of cardiovascular drug therapy has expanded significantly. Using innovative functional genomics strategies such as genome editing by CRISPR/Cas9 as well as high-throughput assays to identify bioactive small chemical compounds has significantly facilitated elaboration of the underlying pathomechanism in various cardiovascular diseases. However, despite scientific progress approvals for cardiovascular drugs has stagnated significantly compared to other fields of drug discovery and therapy during the past years. Areas covered: In this review, the authors discuss the aspects and pitfalls during the early phase of cardiovascular drug discovery and describe the advantages of zebrafish as an in vivo organism to model human cardiovascular diseases (CVD) as well as an in vivo platform for high-throughput chemical compound screening. They also highlight the emerging, promising techniques of automated read-out systems during high-throughput screening (HTS) for the evaluation of important cardiac functional parameters in zebrafish with the potential to streamline CVD drug discovery. Expert opinion: The successful identification of novel drugs to treat CVD is a major challenge in modern biomedical and clinical research. In this context, the definition of the etiologic fundamentals of human cardiovascular diseases is the prerequisite for an efficient and straightforward drug discovery.